New imaging approaches to phaeochromocytomas and paragangliomas

Clinical Endocrinology

Volumn 72, Issue 2, 2010, Pages 137-145

  Havekes, Bas ^a,b   King, Kathryn ^b   Lai, Edwin W ^b   Romijn, Johannes A ^c   Corssmit, Eleonora P M ^c   Pacak, Karel ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SUCCINATE DEHYDROGENASE;

ADRENAL DISEASE; ALGORITHM; ENDOCRINE FUNCTION; HEAD; HUMAN; IMAGING; NECK; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW;

HUMANS; MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 74549170850     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03648.x     Document Type: Review

References (74)

1. Pacak, K., Eisenhofer, G., Ahlman, H. et al. (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nature Clinical Practice. Endocrinology & metabolism, 3, 92 102.
2. Timmers, H.J., Pacak, K., Huynh, T.T. et al. (2008) Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. The Journal of Clinical Endocrinology and Metabolism, 93, 4826 4832.
3. Neumann, H.P., Bausch, B., McWhinney, S.R. et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. The New England Journal of Medicine, 346, 1459 1466.
4. Lenders, J.W., Eisenhofer, G., Mannelli, M. et al. (2005) Phaeochromocytoma. Lancet, 366, 665 675.
5. Brouwers, F.M., Eisenhofer, G., Tao, J.J. et al. (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. The Journal of Clinical Endocrinology and Metabolism, 91, 4505 4509.
6. Jacques, A.E., Sahdev, A., Sandrasagara, M. et al. (2008) Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. European Radiology, 18, 2885 2892.
7. Brindle, K. (2008) New approaches for imaging tumour responses to treatment. Nature Reviews. Cancer, 8, 94 107.
8. Shields, A.F., Mankoff, D.A., Link, J.M. et al. (1998) Carbon-11-thymidine and FDG to measure therapy response. Journal of Nuclear Medicine, 39, 1757 1762.
9. Doubrovin, M., Ponomarev, V., Beresten, T. et al. (2001) Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 9300 9305. (Pubitemid 32743911)
10. van Hagen, P.M., Breeman, W.A., Bernard, H.F. et al. (2000) Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. International Journal of Cancer, 90, 186 198.
11. Miller, J.C., Pien, H.H., Sahani, D. et al. (2005) Imaging angiogenesis: applications and potential for drug development. Journal of the National Cancer Institute, 97, 172 187.
12. Hicks, R.J., Ware, R.E. Lau, E.W. (2006) PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging, 6, S52 S62.
13. Strobel, K., Schaefer, N.G., Renner, C. et al. (2007) Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2- deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Annals of Oncology, 18, 658 664.
14. Sisson, J.C., Frager, M.S., Valk, T.W. et al. (1981) Scintigraphic localization of pheochromocytoma. The New England Journal of Medicine, 305, 12 17.
15. Bravo, E.L. (1994) Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr.Rev., 15, 356 368.
16. Sisson, J.C. Shulkin, B.L. (1999) Nuclear medicine imaging of pheochromocytoma and neuroblastoma. The Quarterly Journal of Nuclear Medicine, 43, 217 223.
17. Furuta, N., Kiyota, H., Yoshigoe, F. et al. (1999) Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. International Journal of Urology, 6, 119 124.
18. Shulkin, B.L., Shapiro, B., Francis, I.R. et al. (1986) Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clinical Nuclear Medicine, 11, 851 854.
19. Shapiro, B., Gross, M.D. Shulkin, B. (2001) Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends in Endocrinology and Metabolism, 12, 469 475.
20. Lumachi, F., Tregnaghi, A., Zucchetta, P. et al. (2006) Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nuclear Medicine Communications, 27, 583 587.
21. Cecchin, D., Lumachi, F., Marzola, M.C. et al. (2006) A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocrine-related Cancer, 13, 525 533.
22. Nakatani, T., Hayama, T., Uchida, J. et al. (2002) Diagnostic localization of extra-adrenal pheochromocytoma: Comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncology Reports, 9, 1225 1227.
23. Nielsen, J.T., Nielsen, B.V. Rehling, M. (1996) Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Clinical Nuclear Medicine, 21, 695 699.
24. Lynn, M.D., Shapiro, B., Sisson, J.C. et al. (1984) Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I] iodobenzylguanidine: concise communication. Journal of Nuclear Medicine, 25, 436 440.
25. Elgazzar, A.H., Gelfand, M.J., Washburn, L.C. et al. (1995) I-123 MIBG scintigraphy in adults. A report of clinical experience. Clinical Nuclear Medicine, 20, 147 152.
26. Eisenhofer, G. (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology & Therapeutics, 91, 35 62.
27. Solanki, K.K., Bomanji, J., Moyes, J. et al. (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nuclear Medicine Communications, 13, 513 521.
28. Ilias, I., Chen, C.C., Carrasquillo, J.A. et al. (2008) Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. Journal of Nuclear Medicine, 49, 1613 1619.
29. Lamberts, S.W., Reubi, J.C. Krenning, E.P. (1993) Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncologica, 32, 167 170.
30. Lastoria, S., Maurea, S., Vergara, E. et al. (1995) Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. The Quarterly Journal of Nuclear Medicine, 39, 145 149.
31. Tenenbaum, F., Lumbroso, J., Schlumberger, M. et al. (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Journal of Nuclear Medicine, 36, 1 6.
32. Kaltsas, G., Korbonits, M., Heintz, E. et al. (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. The Journal of Clinical Endocrinology and Metabolism, 86, 895 902.
33. Giammarile, F., Baudin, E., Tenenbaum, F. et al. (1995) Somatostatin receptor imaging: a preliminary experience in forty-nine patients. The Quarterly Journal of Nuclear Medicine, 39, 121 123.
34. Kwekkeboom, D.J., van, U.H., Pauw, B.K. et al. (1993) Octreotide scintigraphy for the detection of paragangliomas. Journal of Nuclear Medicine, 34, 873 878.
35. van der Harst, E., de Herder, W.W., Bruining, H.A. et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. The Journal of Clinical Endocrinology and Metabolism, 86, 685 693.
36. Schwaiger, M., Kalff, V., Rosenspire, K. et al. (1990) Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation, 82, 457 464.
37. Shulkin, B.L., Wieland, D.M., Schwaiger, M. et al. (1992) PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. Journal of Nuclear Medicine, 33, 1125 1131.
38. Hovevey-Sion, D., Eisenhofer, G., Kopin, I.J. et al. (1990) Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology, 29, 881 887.
39. Beyer, T., Townsend, D.W. Blodgett, T.M. (2002) Dual-modality PET/CT tomography for clinical oncology. The Quarterly Journal of Nuclear Medicine, 46, 24 34.
40. Pacak, K., Linehan, W.M., Eisenhofer, G. et al. (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Annals of Internal Medicine, 134, 315 329.
41. Pacak, K., Eisenhofer, G., Carrasquillo, J.A. et al. (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension, 38, 6 8.
42. Pacak, K., Goldstein, D.S., Doppman, J.L. et al. (2001) A "pheo" lurks: novel approaches for locating occult pheochromocytoma. The Journal of Clinical Endocrinology and Metabolism, 86, 3641 3646.
43. Kaji, P., Carrasquillo, J.A., Linehan, W.M. et al. (2007) The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. European Journal of Endocrinology, 156, 483 487.
44. Timmers, H.J., Hadi, M., Carrasquillo, J.A. et al. (2007) The effects of Carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. Journal of Nuclear Medicine, 48, 1599 1606.
45. Kayani, I. Groves, A.M. (2006) 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clinical Medicine, 6, 240 244.
46. Mann, G.N., Link, J.M., Pham, P. et al. (2006) [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Annals of Surgical Oncology, 13, 187 197.
47. Timmers, H.J., Kozupa, A., Chen, C.C. et al. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology, 25, 2262 2269.
48. Lin, Y.C., Hung, G.U., Luo, T.Y. et al. (2006) A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors. The Journal of Veterinary Medical Science, 68, 367 371.
49. Wild, D., Macke, H.R., Waser, B. et al. (2005) 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. European Journal of Nuclear Medicine and Molecular Imaging, 32, 724.
50. Wild, D., Schmitt, J.S., Ginj, M. et al. (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. European Journal of Nuclear Medicine and Molecular Imaging, 30, 1338 1347.
51. Buchmann, I., Henze, M., Engelbrecht, S. et al. (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 34, 1617 1626.
52. Goldsmith, S.J. (2009) Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncology, 5, 75 84.
53. Neumann, H.P., Pawlu, C., Peczkowska, M. et al. (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA, 292, 943 951.
54. Benn, D.E., Gimenez-Roqueplo, A.P., Reilly, J.R. et al. (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. The Journal of Clinical Endocrinology and Metabolism, 91, 827 836.
55. Timmers, H.J., Kozupa, A., Eisenhofer, G. et al. (2007) Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. The Journal of Clinical Endocrinology and Metabolism, 92, 779 786.
56. Greenblatt, D.Y., Shenker, Y. Chen, H. (2008) The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Annals of Surgical Oncology, 15, 900 905.
57. Miskulin, J., Shulkin, B.L., Doherty, G.M. et al. (2003) Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery, 134, 918 922.
58. Mihai, R., Gleeson, F., Roskell, D. et al. (2008) Routine preoperative (123)I-MIBG scintigraphy for patients with phaeochromocytoma is not necessary. Langenbecks Arch.Surg., 393, 725 727.
59. Benn, D.E. Robinson, B.G. (2006) Genetic basis of phaeochromocytoma and paraganglioma. Best.Pract.Res.Clin.Endocrinol.Metab, 20, 435 450.
60. Bhatia, K.S., Ismail, M.M., Sahdev, A. et al. (2008) (123)I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clinical Endocrinology, 69, 181 188.
61. Timmers, H.J., Carrasquillo, J.A., Whatley, M. et al. (2007) Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. Journal of Nuclear Medicine, 48, 1940 1944.
62. Hoegerle, S., Nitzsche, E., Altehoefer, C. et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology, 222, 507 512.
63. Hoegerle, S., Altehoefer, C., Ghanem, N. et al. (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. European Journal of Nuclear Medicine, 28, 64 71.
64. Hoegerle, S., Altehoefer, C., Ghanem, N. et al. (2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology, 220, 373 380.
65. Huynh, T.T., Pacak, K., Brouwers, F.M. et al. (2005) Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 153, 551 563.
66. Timmers, H.J., Pacak, K., Bertherat, J. et al. (2007) Mutations associated with succinate dehydrogenase d-related malignant paragangliomas. Clinical Endocrinology, 68, 561 566.
67. Havekes, B., Corssmit, E.P., Jansen, J.C. et al. (2007) Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. The Journal of Clinical Endocrinology and Metabolism, 92, 1245 1248.
68. Srirangalingam, U., Khoo, B., Walker, L. et al. (2009) Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocrine-related Cancer, 16, 515 525.
69. Ilias, I., Yu, J., Carrasquillo, J.A. et al. (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. The Journal of Clinical Endocrinology and Metabolism, 88, 4083 4087.
70. van Gelder, T., Verhoeven, G.T., de Jong, P. et al. (1995) Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy. Journal of Nuclear Medicine, 36, 620 622.
71. Zelinka, T., Timmers, H.J., Kozupa, A. et al. (2008) Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocrine-related Cancer, 15, 311 323.
72. Mamede, M., Carrasquillo, J.A., Chen, C.C. et al. (2006) Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nuclear Medicine Communications, 27, 31 36.
73. Gimenez-Roqueplo, A.P., Favier, J., Rustin, P. et al. (2002) Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. The Journal of Clinical Endocrinology and Metabolism, 87, 4771 4774.
74. Warburg, O. (1956) On the origin of cancer cells. Science, 123, 309 314.